Literature DB >> 29032490

Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives.

Maria Ibáñez-Vea1, Miren Zuazo1, Maria Gato1, Hugo Arasanz2, Gonzalo Fernández-Hinojal2, David Escors3, Grazyna Kochan4.   

Abstract

The current knowledge on tumor-infiltrating myeloid-derived suppressor cells (MDSCs) is based mainly on the extensive work performed in murine models. Data obtained for human counterparts are generated on the basis of tumor analysis from patient samples. Both sources of information led to determination of the main suppressive mechanisms used by these cell subsets in tumor-bearing hosts. As a result of the identification of protein targets responsible for MDSCs suppressive activity, different therapeutics agents have been used to eliminate/reduce their adverse effect. In the present work, we review the current knowledge on suppressive mechanisms of MDSCs and therapeutic treatments that interfere with their differentiation, expansion or activity. Based on the accumulation of new evidences supporting their importance for tumor progression and metastasis, the interest in these cell types is increasing. We revise the methods of MDSC generation/differentiation ex vivo that may help in overcoming problems associated with limited numbers of cells available from animals and patients for their study.

Entities:  

Keywords:  Immunosuppression; Immunotherapy; Metastasis; Myeloid regulatory cells; Myeloid-derived suppressor cells (MDSCs); Tumor progression

Mesh:

Year:  2017        PMID: 29032490     DOI: 10.1007/s00005-017-0492-4

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  14 in total

1.  Myeloid-Derived Suppressor Cells and Clinical Outcomes in Children With COVID-19.

Authors:  Katherine Bline; Angel Andrews; Melissa Moore-Clingenpeel; Sara Mertz; Fang Ye; Victoria Best; Rouba Sayegh; Cristina Tomatis-Souverbielle; Ana M Quintero; Zachary Maynard; Rebecca Glowinski; Asuncion Mejias; Octavio Ramilo
Journal:  Front Pediatr       Date:  2022-06-06       Impact factor: 3.569

2.  A novel cancer immunotherapy utilizing autologous tumour tissue.

Authors:  Haemin Park; Matthew Gladstone; Crystal Shanley; Raymond Goodrich; Amanda Guth
Journal:  Vox Sang       Date:  2020-05-06       Impact factor: 2.144

Review 3.  CAR-T Cells for the Treatment of Lung Cancer.

Authors:  Luisa Chocarro; Hugo Arasanz; Leticia Fernández-Rubio; Ester Blanco; Miriam Echaide; Ana Bocanegra; Lucía Teijeira; Maider Garnica; Idoia Morilla; Maite Martínez-Aguillo; Sergio Piñeiro-Hermida; Pablo Ramos; Juan José Lasarte; Ruth Vera; Grazyna Kochan; David Escors
Journal:  Life (Basel)       Date:  2022-04-08

Review 4.  NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma.

Authors:  Chia-Hung Yen; Hui-Hua Hsiao
Journal:  Int J Mol Sci       Date:  2018-11-07       Impact factor: 5.923

5.  Exosomal miRNA-107 induces myeloid-derived suppressor cell expansion in gastric cancer.

Authors:  WeiHong Ren; XuRan Zhang; WenBo Li; Qian Feng; HuiJie Feng; Yan Tong; Hao Rong; Wei Wang; Dai Zhang; ZhenQiang Zhang; ShiChun Tu; XiaoYan Zhu; QinXian Zhang
Journal:  Cancer Manag Res       Date:  2019-05-06       Impact factor: 3.989

Review 6.  Application of PD-1 Blockade in Cancer Immunotherapy.

Authors:  Xiaomo Wu; Zhongkai Gu; Yang Chen; Borui Chen; Wei Chen; Liqiang Weng; Xiaolong Liu
Journal:  Comput Struct Biotechnol J       Date:  2019-05-23       Impact factor: 7.271

Review 7.  Complementing the Cancer-Immunity Cycle.

Authors:  Ruben Pio; Daniel Ajona; Sergio Ortiz-Espinosa; Alberto Mantovani; John D Lambris
Journal:  Front Immunol       Date:  2019-04-12       Impact factor: 7.561

Review 8.  Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?

Authors:  Luisa Chocarro de Erauso; Miren Zuazo; Hugo Arasanz; Ana Bocanegra; Carlos Hernandez; Gonzalo Fernandez; Maria Jesus Garcia-Granda; Ester Blanco; Ruth Vera; Grazyna Kochan; David Escors
Journal:  Front Pharmacol       Date:  2020-04-07       Impact factor: 5.810

Review 9.  Myeloid-derived suppressor cells in transplantation: the dawn of cell therapy.

Authors:  Weitao Zhang; Jiawei Li; Guisheng Qi; Guowei Tu; Cheng Yang; Ming Xu
Journal:  J Transl Med       Date:  2018-01-29       Impact factor: 5.531

Review 10.  Janus-Faced Myeloid-Derived Suppressor Cell Exosomes for the Good and the Bad in Cancer and Autoimmune Disease.

Authors:  Margot Zöller
Journal:  Front Immunol       Date:  2018-02-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.